Finanzas de Avalo Therapeutics, Inc. (AVTX)AVTXAvalo Therapeutics, Inc.

Avalo Therapeutics, Inc. (AVTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Prescription drugs, accounting for 66.9% of total sales, equivalent to $3.62M. Another important revenue stream is Prescribed dietary supplements. Understanding this composition is critical for investors evaluating how AVTX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Avalo Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -36.27%, provide a clear picture of how effectively AVTX converts its operational activities into shareholder value.

In the context of the broader market, AVTX competes directly with industry leaders such as NVCT and PHAR. With a market capitalization of $371.66M, it holds a significant position in the sector. When comparing efficiency, AVTX's gross margin of N/A stands against NVCT's N/A and PHAR's 86.53%. Such benchmarking helps identify whether Avalo Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported a net income loss of -$36,358,000 for Q2 2026 and has a forward P/E ratio of 0, indicating no expected earnings in the near term. Gross margin for Q4 2024 was 54.69%, but subsequent quarters show no revenue, leading to a price-to-sales ratio of 6771.92, indicating overvaluation based on current sales.